- Open Access
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
© Cobb et al. 2015
- Received: 15 December 2014
- Accepted: 17 March 2015
- Published: 12 May 2015
Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate origins, pathogenesis, clinical features, and outcomes. Additionally, previous classification systems for ovarian cancer have proposed two primary histologic groups that encompass the standard histologic subtypes. Recent data suggest that these groupings no longer accurately reflect our knowledge surrounding these cancers. In this review, we propose that epithelial ovarian, tubal, and peritoneal carcinomas represent a spectrum of disease that originates in the Mullerian compartment. We will discuss the incidence, classification, origin, molecular determinants, and pathologic analysis of these cancers that support the conclusion they should be collectively referred to as adenocarcinomas of Mullerian origin. As our understanding of the molecular and pathologic profiling of adenocarcinomas of Mullerian origin advances, we anticipate treatment paradigms will shift towards genomic driven therapeutic interventions.
Adenocarcinoma of Mullerian origin was first described by Dr. Swerdlow in 1959 . The original manuscript entitled, “Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary,” described a patient with a malignant left-sided pelvic mass. The mass surrounded the left fallopian tube without mucosal involvement; bilateral ovaries and the right tube were negative for disease. Histologically, the tumor closely resembled a papillary ovarian cystadenocarcinoma. Dr. Swerdlow theorized that while ovarian or tubal carcinoma was unlikely, the tumor probably developed from tissue with a similar embryological origin as the ovary (specifically, the pelvic peritoneum, fallopian tubes, or uterus). He ultimately concluded that the cancer arose from the pelvic peritoneum . In retrospect, this case represents the earliest documentation of adenocarcinoma of Mullerian origin. There is a growing body of evidence that suggests this terminology applies to epithelial ovarian, peritoneal, and tubal cancers, as well as select cancers previously designated as “cancers of unknown primary” (CUP). Select endometrial cancers may also be included in future classifications, but as the treatment paradigms are different, we chose not to include them in this review.
Ovarian cancer staging (FIGO 2013 vs. FIGO 1988)
I: Tumor limited to the ovaries
I: Tumor confined to ovaries or fallopian tube(s)a
IA: Tumor limited to 1 ovary (capsule intact), no tumor on ovarian surface, no malignant cells in ascites or peritoneal washings
IA: Tumor limited to 1 ovary (capsule intact) or fallopian tube; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
IB: Tumor limited to both ovaries (capsules intact), no tumor on ovarian surface, no malignant cells in ascites or peritoneal washings
IB: Tumor limited to both ovaries (capsules intact) or fallopian tubes; no tumor on ovarian or fallopian tube surface; no malignant cells in the ascites or peritoneal washings
IC: Tumor limited to 1 or both ovaries with any of the following: capsule ruptured, tumor on ovarian surface, malignant cells in ascites or peritoneal washings
IC: Tumor limited to 1 or both ovaries or fallopian tube(s) with any of the following:
IC1: Surgical spill intraoperatively
IC2: Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface
IC3: Malignant cells in the ascites or peritoneal washings
II: Tumor involves 1 or both ovaries with pelvic extension
II: Tumor involves 1 or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or primary peritoneal cancerb
IIA: Extension and/or implants on uterus and/or tube(s); no malignant cells in ascites or peritoneal washings
IIA: Extension and/or implants on uterus and/or fallopian tubes and/or ovaries
IIB: Extension to other pelvic tissues; no malignant cells in ascites or peritoneal washings
IIB: Extension to other pelvic intra-peritoneal tissues
IIC: Pelvic extension (IIA or IIB) with malignant cells in ascites or peritoneal washings
III: Tumor involves 1 or both ovaries with microscopically confirmed peritoneal metastases outside the pelvis and/or regional lymph node metastasis
III: Tumor involves 1 or both ovaries or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes
IIIA: Microscopic peritoneal metastasis beyond pelvis
IIIA1: Positive retroperitoneal lymph nodes only (cytologically or histologically proven)
IIIA1(i): Metastasis up to 10 mm in greatest dimension
IIIA1(ii): Metastasis more than 10 mm in greatest dimension
IIIA2: Microscopic extra-pelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes
IIIB: Macroscopic peritoneal metastasis beyond pelvis, 2 cm or less in greatest dimension
IIIB: Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm in greatest dimension, with or without metastasis to the retro-peritoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)
IIIC: Peritoneal metastasis beyond pelvis more than 2 cm in greatest dimension and/or regional lymph node metastasis
IIIC: Macroscopic peritoneal metastasis beyond the pelvis more than 2 cm in greatest dimension, with or without metastasis to the retro-peritoneal lymph nodes (includes extension of tumor to capsule of liver and spleen without parenchymal involvement of either organ)
IV: Distant metastasis (excludes peritoneal metastasis)
IV: Distant metastasis excluding peritoneal metastases
IVA: Pleural effusion with positive cytology
IVB: Parenchymal metastases and metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity)c
It is difficult to discern how many annual deaths occur due to adenocarcinomas of Mullerian origin. While EOC caused approximately 14,030 deaths in the United States in 2013  and 151,905 deaths worldwide in 2012 , it is unclear exactly how many deaths were caused by peritoneal and tubal cancers. Peritoneal and tubal carcinomas have been considered rare malignancies and separate entities from ovarian carcinomas; thus, epidemiologic studies have proven difficult . Tubal carcinomas account for only 0.14-1.8% of gynecologic malignancies [7,8]. In the United States, from 1995–2004, the age adjusted incidence rates for tubal and peritoneal carcinomas were 3.7 and 6.8 per million, respectively . Newer theories indicate that the number of peritoneal and tubal cancers may be grossly underestimated.
Additionally, CUP accounts for 3-5% of malignant epithelial cancers  and in 2012, there were an estimated 31,000 new cases of CUP in the United States . Potentially 5% of CUP may originate in the female reproductive system based on data from post mortem autopsy studies [9,11]. It is important to recognize the adenocarcinoma of Mullerian origin subset of CUP when it occurs, because these cancers will typically have a more favorable prognosis and sensitivity to platinum-based chemotherapeutic regimens . Identification of adenocarcinoma of Mullerian origin, specifically in patients with CUP, will guide appropriate treatment options, and provide information regarding prognosis [9,12].
Epithelial ovarian cancer classification
EOC classification has changed significantly over the past decade. The most recent proposed division of EOC includes two distinct histologic groups: type I and type II cancers. It should be noted that the type I and type II classification is generally used to broadly classify ovarian neoplasms for research purposes based on their unique clinical and molecular genetic features . The classification was not meant to be used for clinical purposes. Type I tumors include low-grade serous and low-grade endometrioid cancers, as well as mucinous, clear cell, and transitional cell carcinomas. Tumors in this category typically develop from atypical proliferative borderline tumors, benign cystic lesions, or endometriosis. Transitional cell tumors and mucinous tumors do not typically have Mullerian features, but may develop from cortical inclusion cysts and Walthard cell nests . However, there is an uncommon subtype of mucinous tumors which does demonstrate Mullerian (endocervical) characteristics [15,16]. Generally, type I tumors are more indolent, present at an earlier stage, are confined to the ovary, and are often large. When type I tumors, specifically clear cell and mucinous cancers, are not detected early, they usually have a worse prognosis than type II cancers .
Type II cancers account for approximately 75% of EOC and the vast majority of ovarian cancer deaths. These include high-grade serous and high-grade endometrioid carcinomas, as well as carcinosarcomas and undifferentiated carcinomas. These cancers are typically aggressive and diagnosed at a later stage [13,14,17]. Until recently the origin or precursor lesion for the type II cancers was unknown . However, it is now recognized that the precursor lesion exists in the fallopian tube, as discussed later in this review [14,17,19-21].
Fallopian tube cancer classification
As mentioned above, per the 2014 FIGO staging classification, tubal and peritoneal cancers are now considered collectively with ovarian cancer . Regarding histologic classification, serous tubal carcinomas are most frequent (49.5-83.3%), followed by endometrioid (8.3%-50%), mixed (3.9-16.7%), transitional (11.7%), undifferentiated (7.8-11.3%), mucinous (3%-7.6%), and clear cell (1.9%) cancers . These histologic subtypes are similar to the proportions seen in EOC; however, clear cell histology is more common in EOC, while transitional cell and undifferentiated histology is more frequent in tubal cancers [7,8]. In the past, the diagnosis of tubal carcinoma was made based on pathologic criteria with at least one the following: 1) the primary tumor arises from the endosalpinx in the fallopian tube 2) the histologic pattern resembles epithelial mucosa and is often papillary in nature 3) there is a clear transition between benign and malignant epithelium if the wall is involved, and 4) there is no evidence of malignancy in the ovaries or endometrium, or if tumor is present, there is less tumor than is present in the fallopian tube .
Peritoneal cancer classification
Peritoneal carcinomas have been called multiple names including peritoneal papillary serous carcinoma, peritoneal mesothelioma, primary peritoneal carcinoma, and normal-sized ovary carcinoma syndrome. In 1993, the Gynecologic Oncology Group established specific guidelines for the diagnosis of peritoneal carcinoma: 1) ovaries are of normal size or enlarged only as a result of a benign process 2) extraovarian involvement is greater than surface ovarian involvement 3) ovarian involvement does not show evidence of cortical invasion, is confined to the ovarian surface epithelium and cortical stroma and is less than 5×5 mm, and 4) histologically, the cancer is primarily of serous type, appearing similar or identical to ovarian serous adenocarcinoma of any grade . Historically, peritoneal cancers have been reported to be more frequently multifocal with diffuse micronodular spread and more difficult to cytoreduce compared to EOC . In 1994, Fowler et al. characterized the natural history of peritoneal adenocarcinoma of Mullerian origin. He reported that most were classified as serous histology and had either omental disease or diffuse carcinomatosis . Currently, while viewed as separate entities, patients with peritoneal carcinoma are commonly included in ovarian cancer trials, treated similarly to ovarian cancer with cytoreductive surgery and platinum-based chemotherapy , and now considered collectively with ovarian and tubal cancer in the staging guidelines .
Theories regarding adenocarcinoma of Mullerian origin
Ovarian carcinogenesis was previously thought to occur through the invagination of the OSE into the underlying stroma to form inclusion cysts. Metaplasia of the epithelium on the wall of these cysts was proposed to transform the OSE into the aforementioned cell types and their corresponding tumors: serous, mucinous, clear cell, endometrioid and transitional cell carcinomas. This theory seems unlikely for two reasons: (1) the normal ovary does not bear resemblance to the morphologic phenotype of any of these tumors, and (2) it suggests that ovarian cancers develop de novo. However, cancers typically develop in a stepwise fashion from a benign lesion to a malignancy . An alternate theory proposed that ovarian tumors develop from nearby paraovarian and paratubal cysts consisting of Mullerian-type epithelium, called the “secondary Mullerian system.” As the tumors grow from these cysts, they infringe upon the ovary, compress it, and eventually obliterate it, making it appear as though it is ovarian in origin [14,26]. This theory seems unlikely as well, given that paratubal and paraovarian cysts rarely contain precursor lesions resembling serous, clear cell, or endometrioid carcinomas . However, the secondary Mullerian system may also include endosalpingiosis, endometriosis, and endocerviocosis. Metaplasia from these tissues are commonly observed in ovarian malignancies ; thus, this theory may account for the development of some ovarian cancers . The most recent theory proposes that the majority of serous, endometrioid, and clear cell “primary ovarian” cancers actually develop from the fallopian tube and endometrium, the “primary Mullerian system” and will be discussed further in this review [14,27].
Origin of type I EOC
In type I EOC, there is considerable evidence that clear cell and endometrioid carcinomas may originate from endometriosis. The pathogenesis of endometriosis is complex and theories include retrograde menstruation as well as metaplasia of extrauterine cells. Retrograde menstruation would indicate that endometrioid and clear cell cancers develop from endometrial tissue, the primary Mullerian system, which secondarily involves the ovary . Several studies have demonstrated an increased risk of ovarian cancer in the setting of endometriosis [28-30]. A meta-analysis of endometriosis in EOC concluded that the prevalence of endometriosis was significantly higher in women with clear cell cancers (35.9%) and endometrioid carcinomas (19%), compared to those with serous (4.5%), and mucinous (1.4%) cancers .
The origin of mucinous carcinoma is unclear. It is commonly accepted that a majority of mucinous cancers involving the reproductive tract are actually metastases from extraovarian sites, usually gastrointestinal in origin. True primary ovarian mucinous carcinomas are uncommon, accounting for only 3% of ovarian carcinomas, although one recent theory includes mucinous metaplasia of Brenner (transitional cell) tumors . Brenner tumors and mucinous carcinomas (intestinal type) may share similar histogenesis at the tubal peritoneal junction from transitional cell nests that exist there . As mentioned previously, an uncommon subtype of mucinous tumors does demonstrate Mullerian (endocervical) characteristics [15,16]. Most advanced mucinous cancers are likely metastatic gastrointestinal and pancreaticobilliary cancers that involve the ovary and peritoneum.
Origin of type II EOC
While it is not clear how STIC is related to the development of peritoneal cancers, some have hypothesized that sloughed tubal cancer cells disseminate into the peritoneal cavity and implant accordingly. While Sood et al. proposed hematogenous spread of ovarian cancer cells with a predilection for implantation in the omentum , perhaps both modes of metastasis (peritoneal and hematogenous dissemination) play a role in Mullerian carcinogenesis.
Overall, contemporary data indicate that endometrioid and clear cell cancers arise from endometrial tissue with the fallopian tube as a conduit between the uterus, ovary, and peritoneum; serous cancers from STICs in the fallopian tube ; Brenner and mucinous cancers from transitional-type epithelium found at the tubal-peritoneal junction that secondarily implant or metastasize to the ovary and peritoneal surfaces; and rare mucinous cancers from endocervical mucinous neoplasms. Therefore, while historically documented as separate processes, we would argue that ovarian, tubal, and peritoneal cancers should be uniformly referred to as adenocarcinomas of Mullerian origin given their similar pathogenesis.
Disease outcomes for adenocarcinoma of Mullerian origin
In a recent meta-analysis, Sørensen et al. compared serous peritoneal, tubal and ovarian cancer with regards to risk factors, epidemiology, clinicopathology, and molecular biology to address whether these diseases should be considered separately. When comparing peritoneal cancers with ovarian cancers, even though most of these studies were limited by small sample sizes, nine studies showed no significant difference in survival [43-51]. Only three studies showed poorer survival for peritoneal cancers [52-54]; however, two of these studies had a small number of patients with peritoneal cancer [52,53]. When comparing tubal cancers to ovarian cancers, Sørensen et al. sited three studies showing similar survival between these two disease entities [54-56] and two showing improved survival for tubal cancers [57,58]. The studies by Usach et al.  and Wethington et al.  were large studies using the SEER database and did not include information on residual disease after debulking surgery. All of the aforementioned studies had limitations. Most of these studies included small sample sizes, utilized differing definitions of optimal cytoreduction, and failed to include detailed information regarding pathology, surgery, treatment regimens, recurrences, and confounding risk factors, making them difficult to compare and then generalize their findings. Despite an extensive literature search by Sørensen and colleagues, the small number of studies as well as their limitations preclude definitive conclusions regarding survival outcomes between ovarian, tubal, and peritoneal cancers.
Biomarkers and pathologic assessment for adenocarcinoma of Mullerian origin
Serum biomarkers are useful for the detection, response assessment, and prognosis in a variety of solid tumors, including adenocarcinomas of Mullerian origin. Cancer antigen 125 (CA125) is the only biomarker commonly used for monitoring treatment response and cancer progression in EOC , as well as tubal and peritoneal cancers . CA125 is a glycoprotein encoded by the gene MUC16. In patients with advanced EOC, CA125 is elevated (greater than 35 u/mL) approximately 90% of the time. However, in patients with early stage EOC, CA125 is elevated only 50-60% of the time. CA125 is an excellent marker for ovarian cancer, but is nonspecific and can be abnormal in other benign and malignant indications. CA125 expression levels also vary by histology and are elevated in 85% of serous, 65% of endometrioid, 40% of clear cell, and 36% of undifferentiated adenocarcinomas .
There are additional markers that are useful to distinguish between various solid tumors. These include carbohydrate antigen 19–9 (CA19-9), carcinoembryonic antigen (CEA), and human epididymis protein 4 (HE4). CA19-9 is member of the Lewis blood group antigens and is elevated in 27% and 76% of serous and mucinous ovarian cancers, respectively. CEA is a glycoprotein that is expressed in 25-50% of women with EOC and over 80% of patients with colorectal carcinomas. Human epididymis protein 4 (HE4) is overexpressed in serous and endometrioid carcinomas. Unlike CA125, HE4 is more specific to ovarian malignancy and serum levels are usually not elevated with nonmalignant processes . A subset analysis of premenopausal patients enrolled in a prospective clinical trial (NCT00315692) demonstrated that HE4 had a sensitivity of 88.9% and a specificity of 91.8% for the detection of malignancy. In this analysis, invasive malignancy was ruled out for 98% of premenopausal women with an elevated CA-125 and a normal HE4 level . There are other additional markers that have been used in combination with CA125, including cancer antigen 15–3 (CA15-3) and tumor associated glycoprotein 72 (TAG-72). Although CA15-3 is elevated in 57-71% of ovarian malignancies (versus 2-6% of benign ovarian processes), it has a low specificity for ovarian cancer and is primarily used for the diagnosis of breast malignancies. TAG-72 is expressed more commonly in gastrointestinal and pancreatic tumors as well as mucinous ovarian carcinomas . Biomarkers can be useful for identifying adenocarcinomas of Mullerian origin in women with CUP, as well as following response to treatment.
Pathological analysis of adenocarcinoma of Mullerian origin
Ovarian, tubal, and peritoneal cancers have similar pathologic findings which vary based on histologic subtype, but not by primary site of origin. We describe common histopathologic and immunophenotype findings for adenocarcinomas of Mullerian origin stratified by the various subtypes. Pathologic findings support a clear link between serous ovarian, tubal, and peritoneal cancers. However, information regarding pathologic similarities between tubal and peritoneal clear cell, mucinous, and endometrioid carcinomas is minimal given the relatively rare frequency of these histologic subtypes.
High-grade serous carcinoma
HGSCs of the ovary, fallopian tube, and peritoneum are almost identical in histopathology. Microscopically, the architecture could vary from glandular to complex papillary to solid pattern, with the tumor cells infiltrating or replacing the surrounding normal tissues. The papillae are usually large, irregularly branching, and highly cellular. Psammoma bodies may be present in varying numbers, but are rarely as numerous as in LGSC. The marked cytologic atypia and frequent mitotic figures (including atypical ones) characterize HGSC. The tumor cells are enlarged, with high nuclear/cytoplasmic ratio and great variation in size. Tumor giant cells are commonly seen. The nuclei are of high-grade with vesicular chromatin and prominent nucleoli .
Low-grade serous carcinoma
Similar to HGSC, there is strong evidence to support the tubal origin of LGSC . In general, LGSC is characterized by micropapillae and small round nests of neoplastic cells that infiltrate the stroma in a haphazard pattern, with infrequent mitoses and only mild variation in tumor cell size and shape of nuclei. The nuclear/cytoplasmic ratio may be high but the nuclei are uniform, small, and round to oval. Psammoma bodies are common and may be numerous. Necrosis or multinucleated tumor giant cells are not features of LGSC. In contrast to HGSC, LGSC is usually associated with a non-invasive serous borderline component .
As previously discussed, the precursor lesions for LGSC are presumed to be epithelial inclusion cysts (leading to serous cystadenoma/adenofibroma, to atypical serous borderline tumor, to noninvasive micropapillary serous borderline tumor, to invasive LGSCs). These epithelial inclusion cysts were previously thought to arise from invaginations of the OSE that undergo metaplasia; however, the inclusion cysts may originate from tubal epithelia that secondarily implant on disrupted OSE and invaginate . Li et al. demonstrated that OSE primarily has a mesothelial phenotype (calretinin(+)/PAX8(−)), while the majority of epithelial inclusion cysts demonstrate a tubal phenotype (calretinin(−)/PAX8(+)) . It is not surprising then that LGSCs also express PAX8. Additionally, they express ER and WT-1, similar to HGSC. In contrast to HGSC, LGSC is characterized by decreased expression of p53 and p16 (usually negative, scattered, or patchy), and a lower Ki67 proliferative index .
Low-grade serous peritoneal carcinoma is a rare entity; and therefore, available information about this disease is minimal. Schmeler et al. were the first to clinically describe low-grade serous peritoneal cancer. Patients were confirmed to have low-grade serous carcinomas with destructive invasion. Microscopically the cancers had relatively uniform round to oval nuclei, mild to moderate atypia, evenly distributed chromatin, and no more than 12 mitoses per 10 high-power fields (HPF). Additionally, these patients met the previously described GOG criteria for peritoneal carcinoma. Specific immunostaining was not described .
The majority of primary mucinous tumors of the ovary mimic features of gastric or pancreaticobilliary mucinous neoplasms, while another much less common subtype harbor Mullerian (endocervical) characteristics. A spectrum of morphologic changes from cystadenoma to atypical proliferative mucinous tumor (mucinous borderline tumor) to invasive mucinous carcinoma can often be appreciated. They are usually large unilateral neoplasms with a smooth capsule and confined to the ovary at diagnosis (stage I). Stromal invasion may be infiltrative or expansile [15,16]. Mucinous tumors of the fallopian tube and peritoneum are rare, but have been reported [7,8,24,71].
Ovarian mucinous carcinomas display predominance of CK7 over CK20. PAX-8 staining is much less frequent (40%) despite that it is almost universally positive (95–100%) in ovarian serous, endometrioid, and clear cell carcinomas . WT1, ER, PR and p16 are not expressed in primary mucinous carcinomas. p53 protein may be present in 30% of cases, but strong and diffuse overexpression (as found in HGSC) is not characteristic [33,73-75].
Clear cell carcinoma
Clear cell carcinoma has also been associated with endometriosis and displays the following architectural and cytological features: papillary, tubulocystic or solid architecture; hobnail tumor cells with clear cytoplasm; and large, atypical nuclei with conspicuous nucleoli and only moderate polymorphism. Clear cell carcinoma papillae are distinguishable from those of serous carcinoma in that they are short and round, may show eosinophilic and hyalinized stroma, and are generally lined with only one or two layers of cells. Hyaline bodies are present in approximately 25% of cases. Mitoses are less frequent than in other types of ovarian carcinomas (usually < 5 per 10 HPF) [15,16]. While most literature focuses on “ovarian” clear cell carcinoma, there are published case reports of peritoneal and tubal clear cell cancers [76-79]. The histopathologic findings are similar to ovarian clear cell carcinomas, but immunostaining is not consistently available [76-78].
Generally, clear cell carcinomas display a CK7(+)/CK20(-) phenotype; express PAX-8; and lack expression of ER and WT-1. p53 and p16 are usually negative, weak, focal or patchy. Hepatocyte nuclear factor-1β (HNF-1β) is a specific and sensitive marker for ovarian clear cell carcinomas that is not expressed in HGSC [80-82].
Endometrioid carcinomas of the ovary highly resemble endometrioid carcinomas of the uterus in morphology. These cancers may coexist with endometriosis and arise from endometriotic cysts. They are mostly low-grade adenocarcinomas demonstrating a confluent glandular growth pattern with stromal disappearance, or evidence of stromal invasion and squamous metaplasia to varied degrees. Fifteen to thirty percent of patients have concurrent endometrial hyperplasia or carcinoma . Similar histopathologic descriptions have been detailed in few case reports and case series of endometrioid carcinoma of the fallopian tube, but immunostaining was not described in detail [76,84-87]. The even rarer entity of endometrioid carcinoma of the peritoneum has been described in reference to extraovarian endometriosis-associated malignancy [88-90], however specific immunostaining has not been described.
Endometrioid carcinomas typically demonstrate CK7(+)/CK20(-) phenotype; express ER, PR and PAX-8; but lack WT-1 and p16 expression, as well as p53 overexpression. Exceptions to these patterns have been reported in poorly differentiated varieties, which overlap with HGSC in morphology [33,91].
Molecular determinants of adenocarcinoma of Mullerian origin
The data regarding the molecular determinants of adenocarcinoma of Mullerian origin is primarily based on genomic studies of EOC . However, some studies do include tubal and peritoneal cancers. Tothill et al. reported that serous and endometrioid cancers demonstrate a high degree of molecular heterogeneity and could be categorized into six subgroups based on gene expression profiling. Importantly, the primary site of disease could not be used as a classification parameter . Tothill and colleagues reported six distinct subtypes referred to as C1-C6. C3 primarily consisted of serous low malignant potential tumors, while C6 primarily consisted of low-grade, early stage endometrial cancers. C1, C2, C4, and C5 mainly contained high-grade serous and high-grade endometrial cancers. Notably, C5 demonstrated a mesenchymal profile which was associated with relatively poor overall survival . This finding is consistent with our understanding of cells acquiring the mesenchymal phenotype as they acquire invasiveness in the process of epithelial to mesenchymal transition (EMT). However, in the TCGA data set, a correlation between the mesenchymal subtype and survival was not seen . Further evaluation is needed to confirm the associations between gene expression classifications and clinical outcome.
In 2013, Yang and colleagues took an integrated approach (as opposed to the previous transcriptome approach) to analyze serous cancers in the TCGA database and categorize the transcriptional subtypes into integrated mesenchymal and integrated epithelial subtypes. This new approach integrated mRNA expression with associated alterations in genomic, epigenetic, and miRNA systems. With this approach, Yang et al. were able to uncover a master miRNA regulatory network that consistently associated the integrated mesenchymal subtype of serous cancer with poor overall survival .
Additionally, intense interest has focused on using microarray data to identify molecularly-defined subgroups of women with HGSC who may benefit from anti-angiogenic therapy with bevacizumab. Gourley et al. evaluated a cohort of HGSC samples from the ICON7 study and identified three major subgroups; two with upregulation of angiogenic gene expression and one with upregulation of immune genes (and concurrent downregulation of angiogenic genes). Women in the immune subgroup had improved overall and progression-free survival (PFS) over the other two angiogenic subgroups. However, with the incorporation of bevacizumab, the immune subgroup had worse PFS (Hazard ratio (HR) = 1.73 (1.12-2.68)) and overall survival (HR, 2.00 (1.11-3.61)) compared to those treated with chemotherapy alone. In contrast, the pro-angiogenic subgroup treated with bevacizumab had a trend toward improved PFS . Winterhoff and colleagues examined another subgroup of the ICON7 trial and reported that the greatest benefit from bevacizumab appeared in patients with serous carcinomas with the mesenchymal subtype (median PFS increased 9.5 months (25.5 [95%CI 21.1, NA] vs. 16 [95%CI 10.5, NA] months, p = 0.053)) . The results from these studies suggest that bevacizumab therapy may be directed based on molecular subtypes. However, further assessment in a phase III integral biomarker trial is needed to determine if tumor-derived molecular classifications can direct individualized treatment with bevacizumab.
Subtypes of adenocarcinomas of Mullerian origin
Tubal intraepithelial carcinoma
Atypical serous borderline tumor
Metaplasia of transitional cells or metastasis from GI primary tumor*
Positive: p16, CK7, WT-1, PAX-8, ER, CA125, E-cadherin (in most cases), p53
Positive: PAX8, ER, WT-1,
Positive: CK7, PAX-8 (40%), p53 (30%)
Positive: CK7, PAX-8, HNF-1β
Positive: CK7, ER, PR, PAX-8
Negative: Her-2, calretinin, CK20
Negative: p53 and p16 (negative, scattered or patchy)
Negative: WT-1, ER, PR and p16
Negative: CK20, ER, WT-1, p53 and p16 (negative, weak, focal or patchy)
Negative: WT-1, p16, CK 20, p53
BRAF, KRAS, NRAS mutations
Inherited BRCA1/2 mutation
High-grade serous ovarian, tubal, and peritoneal carcinoma
High-grade Mullerian cancers display predominantly serous histology, but also include some endometrial carcinomas, carcinosarcomas, and undifferentiated cancers. While less is known about the molecular profile of undifferentiated Mullerian tumors and carcinosarcomas, it appears that gene expression profiles and genetic alterations are very similar to those found in serous carcinomas [97,98]. These tumors exhibit a high level of genetic instability and are characterized by extensive chromosomal alterations and mutation of the tumor suppressor gene, TP53 [99,100]. Mutation of TP53 is an early event in the pathogenesis of HGSC and is found in STICs [20,101]. The presence of TP53 mutations is nearly ubiquitous (>95%) in HGSC, thus it is not a useful prognostic or predictive biomarker .
The Cancer Genome Atlas (TCGA) Project recently analyzed mRNA and microRNA expression, exome sequencing of entire coding regions, copy number alterations, and methylation of 489 HGSC . The high degree of genomic instability in these cancers is notable with 30 regional chromosomal aberrations (8 recurrent gains and 22 losses), 63 focal areas of amplification, and 50 focal deletions. By comparison, there were few mutations in individual genes identified. TP53 was mutated in nearly all cases (>95%) and the next most commonly mutated genes were BRCA1 and BRCA2 (germline mutations present in 9% and 8% respectively, with somatic mutations in an additional 3% of cases). BRCA inactivation leads to defective repair of double stranded DNA breaks by homologous recombination. Although germline and somatic mutations of BRCA1 and BRCA2 account for <15% of cases, it was estimated that defects in homologous recombination genes, such as EMSY, PTEN, RAD51C, ATM/ATR, and Fanconi anemia genes, are present in 50% of all HGSC . This may indicate that a large proportion of HGSC may be sensitive to treatments targeting DNA repair, such as PARP1 inhibitors.
Significant alterations have also been identified in the PI3K-AKT pathway. However, unlike type I cancers (such as clear cell or low-grade endometrioid cancers, which exhibit mutations in PTEN and PIK3CA), the pathway alterations in HGSCs are characterized by deletions (PTEN) and amplifications (PIK3CA, KRAS, and AKT1/2). Mutations in each individual gene account for <1% of the alterations. Similarly the retinoblastoma (Rb) signaling pathway is altered in 67% of cases with frequent down-regulation of CDKN2A (30%), deletion of RB1 (8%), and amplification of CCNE1 (20%), with few mutations found in these genes [92,102]. These data further support the finding that HGSC are characterized by generalized genomic instability rather than point mutations of driver genes.
Molecular signatures have been identified that are prognostic and/or predictive of response to therapy [103,104]. Whether or how these molecular signatures could guide clinical care is unclear. Confirmation of the initial results as well as biomarker-directed therapeutic trials are needed to determine if molecular signatures can be used to guide therapy in women with HGSC.
Low-grade serous carcinoma
Unlike HGSC, LGSCs do not exhibit chromosomal instability and are not associated with TP53 or BRCA mutations [105,106]. Instead, mutations in the MAP kinase pathway are common with mutations in BRAF (38%) and KRAS (19%) the most frequent [107-109] as well as NRAS mutations . These mutations also appear to be mutually exclusive [35,107]. In addition to the MAPK pathway mutations, LGSCs are more likely to exhibit increased expression of ER/PR, E-cadherin, PAX2, and IGF-1 compared to HGSC . LGSC typically responds poorly to cytotoxic chemotherapy with an average response rate of only 4% in women with recurrent disease . Based on studies suggesting that mutations in MAPK pathway genes act as driver mutations, inhibitors of the MAPK pathway, and in particular MEK inhibitors, are of great interest. Indeed, this has led to the trial of MAPK inhibitors for the treatment of women with recurrent LGSC. In a phase II trial of selumetinib, a MEK1/2 inhibitor, 15% of patients had an objective response to therapy and 65% had stable disease . Further trials are ongoing, but these results present the potential of targeted individualized therapy based on a molecular understanding of the disease.
Unlike HGSCs, in which TP53 and BRCA mutations are most common, these mutations are relatively rare in mucinous tumors. Instead, the majority of mucinous tumors exhibit either HER2 amplification or KRAS mutation . The KRAS gene encodes the K-Ras protein, a key member of the RAS/RAF/MEK/ERK/MAP kinase signaling pathway that transduces various growth signals from the cell surface to the nucleus. KRAS mutations resulting in constitutive activation of the G protein are commonly found in codons 12, 13, and 61 and have been identified in a number of solid tumors . KRAS mutations have been described in up to 68% of cases of mucinous ovarian cancer, while present in only 5% of non-mucinous tumors [113,115,116]. The large majority of mutations were identified in codon 12 (94%) . KRAS mutations are thought to occur early in the development of these cancers as they are found in benign, low malignant potential, and borderline tumors of mucinous histology [117,118]. The high level of KRAS mutations in mucinous ovarian cancer may have treatment implications as targeted agents are being developed to target KRAS mutated tumors.
Overexpression/amplification of HER2 (ERBB2), a member of the epidermal growth factor receptor family that acts upstream of KRAS, has been identified in up to 35% of mucinous ovarian cancer cases [113,119-121]. Ethnic differences may exist as HER2 positivity was higher in Asian cohorts [119-121]. While no association was identified between HER2 status and outcomes, responses of HER2 amplified mucinous ovarian tumors to HER2 directed therapy have been reported [120-123].
Clear cell carcinoma
Similar to the other type I Mullerian carcinomas, clear cell carcinomas are not associated with chromosomal instability or mutations in TP53 or BRCA. Notably, clear cell carcinomas of Mullerian origin exhibit distinctive gene expression profiles from other Mullerian histologies, while sharing significant expression patterns with clear cell tumors of the kidney and endometrium [124,125]. Ovarian clear cell carcinomas show increased activation of angiogenic, hypoxic cell growth, and glucose metabolic pathways and demonstrate increased sensitivity to anti-angiogenic therapies . Clinical trials using anti-angiogenic tyrosine kinase inhibitors are currently in progress.
Nearly 50% of clear cell ovarian carcinomas were found to harbor ARID1A mutations resulting in loss of its encoded protein, BAF250a, a subunit of the SWI-SNF chromatin remodeling complex . Loss of BAF250a expression is thought to be an early event in the pathogenesis of clear cell tumors as endometriotic cyst epithelium in direct contact with the tumor also exhibited loss of expression while cyst epithelium remote to the tumor did not . Studies have shown that ARID1A acts as a tumor suppressor and coordinates with p53 protein to regulate cellular growth . However, inactivating mutations of ARID1A alone do not appear to be sufficient for tumor formation, but likely require additional genetic alterations resulting in activation of the PI3K-Akt pathway [130,131]. Activating mutations in PIK3CA are found in 33% of cases, PTEN loss in 12%, with alterations in PI3K-Akt pathway occurring in 62% [131,132]. Preclinical studies suggest that targeting the PI3K-Akt pathway inhibits clear cell carcinoma tumor growth in a mouse model and that loss of ARID1A further sensitizes cells to PI3K- and Akt-inhibition [133,134]. Clinical trials of agents targeting the PI3K-Akt pathway are ongoing (NCT02142803, NCT01196429).
Similar to the dualistic pathway of pathogenesis of serous carcinomas, molecular profiling of high-grade endometrioid carcinomas are notable for mutations in TP53 with the absence of other molecular alterations, while low-grade endometrioid carcinomas were strongly associated with microsatellite instability (20%), CTNNB1 mutations (~50%), and KRAS mutations (up to 35%) [135-137]. High-grade endometrioid carcinomas were found to have a gene expression profile similar to HGSC . Low-grade endometrioid carcinomas, however, are similar to clear cell adenocarcinomas in their association with endometriosis, expression of ARID1A mutations, and activation of the PI3K-Akt pathway. Ovarian endometrioid carcinomas are characterized by frequent somatic ARID1A inactivating mutations (30-55% of cases) [127,137,138]. Mutations typically are deletion or nonsense mutations which result in loss of protein expression . ARID1A loss is associated with loss of PTEN and mutations in PIK3CA resulting in increased activation of the PI3K-Akt pathway . It has been demonstrated in a genetically engineered mouse model that co-deletion of ARID1A and PTEN results in the formation of ovarian carcinoma with morphological and molecular features resembling human ovarian endometrioid carcinoma . Activating mutations of PIK3CA are found in 20% of endometrioid carcinomas, while mutations in PTEN are present in 14-20%, and loss of heterozygosity of PTEN was present in 42% [136,137,141,142]. Loss of ARID1A has also been identified in endometrial hyperplasia with atypia, the precursor lesion of endometrioid carcinoma, and appears to be an early event in its pathogenesis . However, despite the similarities between clear cell carcinomas and endometrioid carcinomas in ARID1A and PI3K-Akt pathway aberrations, protein array analysis showed differential expression between the two subtypes with endometrioid carcinomas expressing higher levels of steroid hormone receptors (ER and PR), and clear cell carcinomas expressing higher levels of Cyclin E, SMAD3, and e-cadherin . Similarly, BRAF mutations were identified in 24% of endometrioid carcinomas, but were not identified in any case of clear cell carcinoma .
Other mutations frequently found in low-grade endometrioid carcinomas include mutations in CTNNB1 (the gene that encodes beta-catenin) and mutations in mismatch repair genes. Mutations in CTNNB1 are found in up to 50% of endometrioid ovarian tumors and are associated with improved outcomes [135-137]. Mutations typically result in over-expression of nuclear beta-catenin and increased transcription of down-stream target genes, such as the proto-oncogene MYC. These changes are present in a majority of borderline endometrioid ovarian tumors suggesting it is an early event in tumorigenesis . Patients with Lynch syndrome are also at risk for developing EOC, most commonly the endometrioid subtype. Microsatellite instability has been detected in up to 20% of endometrioid tumors . Similar to other Lynch-associated tumors, these tumors often exhibit abnormal mismatch repair protein expression with complete loss of MLH1, MSH2, MSH6, and/or PMS2 .
Our review of the molecular, genetic, and histopathologic data supports the comprehensive inclusion of epithelial ovarian, tubal, and peritoneal cancers, as well as select CUP, as adenocarcinomas of Mullerian origin. While the dualistic Type I and II model of epithelial ovarian cancer suggests two main categories, it is unclear if this model can be extended to adenocarcinomas of Mullerian origin. However, it is clear that the different histologic subtypes within these categories are distinct with regard to clinical outcome, pathophysiologic, and molecular features which may have therapeutic implications. In light of the aforementioned advancements in genomics we propose a new nomenclature for this set of diseases. The terminology may include adenocarcinoma of Mullerian origin, followed by presumed primary site (ovary, fallopian tube, peritoneum), histologic subtype, and mutation status (if relevant). This type of nomenclature would appropriately capture the similarities among adenocarcinomas of Mullerian origin in both origin and histology, but recognize the unique molecular differences between them, all of which inform treatment decisions and prognosis. An example of such a classification could be “adenocarcinoma of Mullerian origin, fallopian tube primary, high-grade serous histology, BRCA1 mutation." Currently, the standard treatment of adenocarcinomas of Mullerian origin includes cytoreductive surgery and multi-agent platinum-based chemotherapy. The advances made in understanding the underlying molecular determinants of adenocarcinomas of Mullerian origin, as well as development of targeted therapeutics, will enable the implementation of genomic-driven treatment decisions in the future, elucidation of novel targets that can be used in preventive strategies, and better identification of precursor lesions that will yield improved survival outcomes.
We’d like to thank Rex Bentley, MD in the Duke Department of Pathology for providing the additional pathologic images used in Figure 4.
- Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol. 1959;77(1):197–200.PubMedGoogle Scholar
- Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5. doi:10.1016/j.ijgo.2013.10.001.PubMedView ArticleGoogle Scholar
- Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 2014. doi:10.1007/s00404-014-3364-8.Google Scholar
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.PubMedView ArticleGoogle Scholar
- Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F., 2012 G. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. In: Lyon FIAfRoC, editor. Internet. Lyon, France2012.Google Scholar
- Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol Biomarkers Prev. 2009;18(1):132–9. doi:10.1158/1055-9965.epi-08-0771.PubMed CentralPubMedView ArticleGoogle Scholar
- Pectasides D, Pectasides E, Economopoulos T. Fallopian tube carcinoma: a review. Oncologist. 2006;11(8):902–12. doi:10.1634/theoncologist.11-8-902.PubMedView ArticleGoogle Scholar
- Kalampokas E, Kalampokas T, Tourountous I. Primary fallopian tube carcinoma. Eur J Obstet Gynecol Reprod Biol. 2013;169(2):155–61. doi:10.1016/j.ejogrb.2013.03.023.PubMedView ArticleGoogle Scholar
- Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379(9824):1428–35. doi:10.1016/s0140-6736(11)61178-1.PubMedView ArticleGoogle Scholar
- Kim KW, Krajewski KM, Jagannathan JP, Nishino M, Shinagare AB, Hornick JL, et al. Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know. AJR Am J Roentgenol. 2013;200(3):484–92. doi:10.2214/ajr.12.9363.PubMed CentralPubMedView ArticleGoogle Scholar
- Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43(14):2026–36. doi:10.1016/j.ejca.2007.06.023.PubMedView ArticleGoogle Scholar
- Fowler JM, Nieberg RK, Schooler TA, Berek JS. Peritoneal adenocarcinoma (serous) of Mullerian type: a subgroup of women presenting with peritoneal carcinomatosis. Int J Gynecol Cancer. 1994;4(1):43–51.PubMedView ArticleGoogle Scholar
- Koshiyama M, Matsumura N. Recent concepts of ovarian carcinogenesis: type I and type II. 2014;2014:934261. doi:10.1155/2014/934261.Google Scholar
- Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433–43. doi:10.1097/PAS.0b013e3181cf3d79.PubMed CentralPubMedView ArticleGoogle Scholar
- Prat J. New insights into ovarian cancer pathology. Ann Oncol. 2012;23 suppl 10:x111–x7. doi:10.1093/annonc/mds300.PubMedView ArticleGoogle Scholar
- Soslow RA. Histologic Subtypes of Ovarian Carcinoma: An Overview. Int J Gynecol Pathol. 2008;27(2):161–74. doi:10.1097/PGP.0b013e31815ea812.PubMedGoogle Scholar
- Erickson BK, Conner MG, Landen Jr CN. The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol. 2013;209(5):409–14. doi:10.1016/j.ajog.2013.04.019.PubMed CentralPubMedView ArticleGoogle Scholar
- Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4(10):814–9. doi:10.1038/nrc1457.PubMedView ArticleGoogle Scholar
- Piek JM, Verheijen RH, Kenemans P, Massuger LF, Bulten H, van Diest PJ. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol. 2003;90(2):491.PubMedView ArticleGoogle Scholar
- Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma–evidence supporting the clonal relationship of the two lesions. J Pathol. 2012;226(3):421–6. doi:10.1002/path.3023.PubMedView ArticleGoogle Scholar
- Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161–9. doi:10.1097/01.pas.0000213335.40358.47.PubMedView ArticleGoogle Scholar
- C Nay Fellay MF, Delaloye FF, Bauer J. Extraovarian Primary Peritoneal Carcinoma. Management of Rare Adult Tumours. Paris: Springer Publishing Company; 2010. p. 279–92.Google Scholar
- Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol. 2010;75(1):27–42. doi:10.1016/j.critrevonc.2009.10.003.PubMedView ArticleGoogle Scholar
- Roh SY, Hong SH, Ko YH, Kim TH, Lee MA, Shim BY, et al. Clinical characteristics of primary peritoneal carcinoma. Cancer Res Treat. 2007;39(2):65–8. doi:10.4143/crt.2007.39.2.65.PubMed CentralPubMedView ArticleGoogle Scholar
- Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev. 2001;22(2):255–88. doi:10.1210/edrv.22.2.0422.PubMedGoogle Scholar
- Lauchlan SC. The secondary Mullerian system. Obstet Gynecol Surv. 1972;27(3):133–46.PubMedView ArticleGoogle Scholar
- Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol. 2012;5:8. doi:10.1186/1756-8722-5-8.PubMed CentralPubMedView ArticleGoogle Scholar
- Kobayashi H, Sumimoto K, Moniwa N, Imai M, Takakura K, Kuromaki T, et al. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer. 2007;17(1):37–43. doi:10.1111/j.1525-1438.2006.00754.x.PubMedView ArticleGoogle Scholar
- Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol. 1997;176(3):572–9.PubMedView ArticleGoogle Scholar
- Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril. 2004;82(2):405–14. doi:10.1016/j.fertnstert.2004.02.109.PubMedView ArticleGoogle Scholar
- Van Gorp T, Amant F, Neven P, Vergote I, Moerman P. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol. 2004;18(2):349–71. doi:10.1016/j.bpobgyn.2003.03.001.PubMedView ArticleGoogle Scholar
- Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013;45(3):229–42. doi:10.1097/PAT.0b013e32835f2264.PubMedView ArticleGoogle Scholar
- Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267–82. doi:10.1097/PAP.0b013e3181b4fffa.PubMed CentralPubMedView ArticleGoogle Scholar
- Alvarez AA, Moore WF, Robboy SJ, Bentley RC, Gumbs C, Futreal PA, et al. K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary. Gynecol Oncol. 2001;80(2):201–6. doi:10.1006/gyno.2000.6066.PubMedView ArticleGoogle Scholar
- Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Sharma R, Russell P et al. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS-pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clin Cancer Res. 2014. doi:10.1158/1078-0432.ccr-14-1292.Google Scholar
- Vang R, Shih Ie M, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology. 2013;62(1):44–58. doi:10.1111/his.12046.PubMedView ArticleGoogle Scholar
- Li J, Abushahin N, Pang S, Xiang L, Chambers SK, Fadare O, et al. Tubal origin of 'ovarian' low-grade serous carcinoma. Mod Pathol. 2011;24(11):1488–99. doi:10.1038/modpathol.2011.106.PubMedView ArticleGoogle Scholar
- Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195(4):451–6. doi:10.1002/path.1000.PubMedView ArticleGoogle Scholar
- Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211(1):26–35. doi:10.1002/path.2091.PubMedView ArticleGoogle Scholar
- Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34(10):1407–16. doi:10.1097/PAS.0b013e3181ef7b16.PubMedView ArticleGoogle Scholar
- Dehari R, Kurman RJ, Logani S, Shih IM. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol. 2007;31(7):1007–12. doi:10.1097/PAS.0b013e31802cbbe9.PubMedView ArticleGoogle Scholar
- Pradeep S, Kim SW, Wu SY, Nishimura M, Chaluvally-Raghavan P, Miyake T, et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell. 2014;26(1):77–91. doi:10.1016/j.ccr.2014.05.002.PubMedPubMed CentralView ArticleGoogle Scholar
- Bloss JD, Liao SY, Buller RE, Manetta A, Berman ML, McMeekin S, et al. Extraovarian peritoneal serous papillary carcinoma: a case–control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol. 1993;50(3):347–51. doi:10.1006/gyno.1993.1223.PubMedView ArticleGoogle Scholar
- Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, Clarke-Pearson DL. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma—a Gynecologic Oncology Group Study. Gynecol Oncol. 2003;89(1):148–54. doi:http://dx.doi.org/10.1016/S0090-8258(03)00068-4.PubMedView ArticleGoogle Scholar
- Khalifeh I, Munkarah AR, Lonardo F, Malone JM, Morris R, Lawrence WD, et al. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Int J Gynecol Pathol. 2004;23(2):162–9.PubMedView ArticleGoogle Scholar
- Killackey MA, Davis AR. Papillary Serous Carcinoma of the Peritoneal Surface: Matched-Case Comparison with Papillary Serous Ovarian Carcinoma. Gynecol Oncol. 1993;51(2):171–4. doi:http://dx.doi.org/10.1006/gyno.1993.1267.PubMedView ArticleGoogle Scholar
- Barda G, Menczer J, Chetrit A, Lubin F, Beck D, Piura B, et al. Comparison between primary peritoneal and epithelial ovarian carcinoma: a population-based study. Am J Obstet Gynecol. 2004;190(4):1039–45. doi:10.1016/j.ajog.2003.09.073.PubMedView ArticleGoogle Scholar
- Ayhan A, Taskiran C, Yigit-Celik N, Bozdag G, Gultekin M, Usubutun A, et al. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer? Int J Gynecol Cancer. 2006;16(2):484–9. doi:10.1111/j.1525-1438.2006.00590.x.PubMedView ArticleGoogle Scholar
- Dubernard G, Morice P, Rey A, Camatte S, Fourchotte V, Thoury A, et al. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur J Surg Oncol. 2004;30(9):976–81. doi:http://dx.doi.org/10.1016/j.ejso.2004.08.005.PubMedView ArticleGoogle Scholar
- Dalrymple JC, Bannatyne P, Russell P, Solomon HJ, Tattersall MHN, Atkinson K, et al. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. Cancer. 1989;64(1):110–5. doi:10.1002/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5.PubMedView ArticleGoogle Scholar
- Schorge JO, Miller YB, Qi L-J, Muto MG, Welch WR, Berkowitz RS, et al. Genetic Alterations of the WT1 Gene in Papillary Serous Carcinoma of the Peritoneum. Gynecol Oncol. 2000;76(3):369–72. doi:http://dx.doi.org/10.1006/gyno.1999.5711.PubMedView ArticleGoogle Scholar
- Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer. 2001;11(5):403–8.PubMedView ArticleGoogle Scholar
- Eisenhauer EL, Sonoda Y, Levine DA, Abu-Rustum NR, Gemignani ML, Sabbatini PJ, et al. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. Am J Obstet Gynecol. 2008;198(2):213.e1–e7. doi:http://dx.doi.org/10.1016/j.ajog.2007.07.003.View ArticleGoogle Scholar
- Schnack TH, Sorensen RD, Nedergaard L, Hogdall C. Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology–a prospective comparative study. Gynecol Oncol. 2014;135(2):278–84. doi:10.1016/j.ygyno.2014.08.020.PubMedView ArticleGoogle Scholar
- Dunn MS, Manahan KJ, Geisler JP. Primary carcinoma of the fallopian tube and epithelial ovarian carcinoma: A case–control analysis. J Reprod Med. 2008;53(9):691–4.PubMedGoogle Scholar
- Moore KN, Moxley KM, Fader AN, Axtell AE, Rocconi RP, Abaid LN, et al. Serous fallopian tube carcinoma: A retrospective, multi-institutional case–control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol. 2007;107(3):398–403. doi:http://dx.doi.org/10.1016/j.ygyno.2007.09.027.PubMedView ArticleGoogle Scholar
- Usach I, Blansit K, Chen LM, Ueda S, Brooks R, Kapp DS, et al. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas. Am J Obstet Gynecol. 2015;212(2):188.e1–6. doi:10.1016/j.ajog.2014.08.016.View ArticleGoogle Scholar
- Wethington SL, Herzog TJ, Seshan VE, Bansal N, Schiff PB, Burke WM, et al. Improved survival for fallopian tube cancer. Cancer. 2008;113(12):3298–306. doi:10.1002/cncr.23957.PubMedView ArticleGoogle Scholar
- Tanyi JL, Scholler N. Oncology biomarkers for gynecologic malignancies. Front Biosci. 2012;4:1097–110.View ArticleGoogle Scholar
- Levy T, Weiser R, Boaz M, Ben Shem E, Golan A, Menczer J. The significance of the pattern of serum CA125 level ascent to above the normal range in epithelial ovarian, primary peritoneal and tubal carcinoma patients. Gynecol Oncol. 2013;129(1):165–8. doi:http://dx.doi.org/10.1016/j.ygyno.2012.12.024.PubMedView ArticleGoogle Scholar
- Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 2011;205(4):358.e1–6. doi:10.1016/j.ajog.2011.05.017.View ArticleGoogle Scholar
- Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol. 2008;21(9):1147–55.PubMedView ArticleGoogle Scholar
- Kobel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E, et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33(1):14–21. doi:10.1097/PAS.0b013e3181788546.PubMedView ArticleGoogle Scholar
- Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34(5):627–35. doi:10.1097/PAS.0b013e3181da7687.PubMedGoogle Scholar
- Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol. 2002;117(6):944–51. doi:10.1309/2t1y-7bb7-dape-pq6l.PubMedView ArticleGoogle Scholar
- Wiseman W, Michael CW, Roh MH. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Mullerian carcinoma in effusions. Diagn Cytopathol. 2011;39(9):651–6. doi:10.1002/dc.21442.PubMedView ArticleGoogle Scholar
- Hou T, Liang D, He J, Chen X, Zhang Y. Primary peritoneal serous carcinoma: a clinicopathological and immunohistochemical study of six cases. Int J Clin Exp Pathol. 2012;5(8):762–9.PubMed CentralPubMedGoogle Scholar
- Liu Q, Lin JX, Shi QL, Wu B, Ma HH, Sun GQ. Primary peritoneal serous papillary carcinoma: a clinical and pathological study. Pathol Oncol Res. 2011;17(3):713–9. doi:10.1007/s12253-011-9375-x.PubMedView ArticleGoogle Scholar
- Attanoos RL, Webb R, Dojcinov SD, Gibbs AR. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology. 2002;40(3):237–44.PubMedView ArticleGoogle Scholar
- Schmeler KM, Sun CC, Malpica A, Deavers MT, Bodurka DC, Gershenson DM. Low-grade serous primary peritoneal carcinoma. Gynecol Oncol. 2011;121(3):482–6. doi:10.1016/j.ygyno.2011.02.017.PubMedView ArticleGoogle Scholar
- Seidman JD. Mucinous lesions of the fallopian tube. A report of seven cases. Am J Surg Pathol. 1994;18(12):1205–12.PubMedView ArticleGoogle Scholar
- Ozcan A, Shen SS, Hamilton C, Anjana K, Coffey D, Krishnan B, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24(6):751–64. doi:10.1038/modpathol.2011.3.PubMedView ArticleGoogle Scholar
- Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer. 2003;97(2):389–404. doi:10.1002/cncr.11064.PubMedView ArticleGoogle Scholar
- Kamal CK, Simionescu CE, Margaritescu C, Stepan A. P53 and Ki67 immunoexpression in mucinous malignant ovarian tumors. Rom J Morphol Embryol. 2012;53(3 Suppl):799–803.PubMedGoogle Scholar
- Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004;23(2):110–8.PubMedView ArticleGoogle Scholar
- Alvarado-Cabrero I, Young RH, Vamvakas EC, Scully RE. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol. 1999;72(3):367–79. doi:10.1006/gyno.1998.5267.PubMedView ArticleGoogle Scholar
- de la Torre FJ, Rojo F, Garcia A. Clear cells carcinoma of fallopian tubes associated with tubal endometriosis. Case report and review. Arch Gynecol Obstet. 2002;266(3):172–4.PubMedView ArticleGoogle Scholar
- Ryuko K, Iwanari O, Abu-Musa A, Fujiwaki R, Kitao M. Primary clear cell adenocarcinoma of the fallopian tube with brain metastasis: a case report. Asia-Oceania J Obstet Gynaecol. 1994;20(2):135–40.PubMedView ArticleGoogle Scholar
- Wuntakal R, Lawrence A. Are oestrogens and genetic predisposition etiologic factors in the development of clear cell carcinoma of the peritoneum? Med Hypotheses. 2013;80(2):167–71. doi:10.1016/j.mehy.2012.11.021.PubMedView ArticleGoogle Scholar
- Phillips V, Kelly P, McCluggage WG. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int J Gynecol Pathol. 2009;28(2):179–86. doi:10.1097/PGP.0b013e318182c2d2.PubMedView ArticleGoogle Scholar
- DeLair D, Oliva E, Kobel M, Macias A, Gilks CB, Soslow RA. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol. 2011;35(1):36–44. doi:10.1097/PAS.0b013e3181ff400e.PubMedView ArticleGoogle Scholar
- Cameron RI, Ashe P, O'Rourke DM, Foster H, McCluggage WG. A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol. 2003;22(3):272–6. doi:10.1097/01.pgp.0000071044.12278.43.PubMedView ArticleGoogle Scholar
- Irving JA, Catasus L, Gallardo A, Bussaglia E, Romero M, Matias-Guiu X, et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol. 2005;36(6):605–19. doi:10.1016/j.humpath.2005.03.005.PubMedView ArticleGoogle Scholar
- Fujiwaki R, Takahashi K, Ryuko K, Watanabe Y, Nishiki Y, Kitao M. Primary endometrioid carcinoma of the fallopian tube. Acta Obstet Gynecol Scand. 1996;75(5):508–10.PubMedView ArticleGoogle Scholar
- Navani SS, Alvarado-Cabrero I, Young RH, Scully RE. Endometrioid carcinoma of the fallopian tube: a clinicopathologic analysis of 26 cases. Gynecol Oncol. 1996;63(3):371–8. doi:10.1006/gyno.1996.0338.PubMedView ArticleGoogle Scholar
- Rabczynski J, Ziolkowski P. Primary endometrioid carcinoma of fallopian tube. Clinicomorphologic study. Pathol Oncol Res. 1999;5(1):61–6.PubMedView ArticleGoogle Scholar
- Alvarado-Cabrero I, Navani SS, Young RH, Scully RE. Tumors of the fimbriated end of the fallopian tube: a clinicopathologic analysis of 20 cases, including nine carcinomas. Int J Gynecol Pathol. 1997;16(3):189–96.PubMedView ArticleGoogle Scholar
- Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol. 2002;100(4):788–95.PubMedView ArticleGoogle Scholar
- Heaps JM, Nieberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol. 1990;75(6):1023–8.PubMedGoogle Scholar
- Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF, Robboy SJ. Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol. 2001;20(2):133–9.PubMedView ArticleGoogle Scholar
- Caduff RF, Svoboda-Newman SM, Bartos RE, Ferguson AW, Frank TS. Comparative analysis of histologic homologues of endometrial and ovarian carcinoma. Am J Surg Pathol. 1998;22(3):319–26.PubMedView ArticleGoogle Scholar
- Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. doi:10.1038/nature10166.Google Scholar
- Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198–208. doi:10.1158/1078-0432.ccr-08-0196.PubMedView ArticleGoogle Scholar
- Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot Chad V, et al. Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer. Cancer Cell. 2013;23(2):186–99. doi:http://dx.doi.org/10.1016/j.ccr.2012.12.020.PubMed CentralPubMedView ArticleGoogle Scholar
- Gourley C, McCavigan A, Perren T, Paul J, Michie CO, Churchman M, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol. 2014;32(5s):(suppl; abstr 5502).Google Scholar
- Boris JN, Winterhoff SK, Oberg AL, Wang C, Riska SM, Konecny GE, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. J Clin Oncol. 2014;32(5s):(suppl; abstr 5509).Google Scholar
- Lisowska KM, Olbryt M, Dudaladava V, Pamula-Pilat J, Kujawa K, Grzybowska E, et al. Gene expression analysis in ovarian cancer - faults and hints from DNA microarray study. Front Oncol. 2014;4:6. doi:10.3389/fonc.2014.00006.PubMed CentralPubMedView ArticleGoogle Scholar
- Schipf A, Mayr D, Kirchner T, Diebold J. Molecular genetic aberrations of ovarian and uterine carcinosarcomas–a CGH and FISH study. Virchows Arch. 2008;452(3):259–68. doi:10.1007/s00428-007-0557-6.PubMedView ArticleGoogle Scholar
- Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P et al. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PloS One. 2010;5(9). doi:10.1371/journal.pone.0011408.Google Scholar
- Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56. doi:10.1002/path.2696.PubMed CentralPubMedView ArticleGoogle Scholar
- Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W, et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci. 2011;3:625–34.View ArticleGoogle Scholar
- Espinosa I, Catasus L, Canet B, D'Angelo E, Munoz J, Prat J. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Mod Pathol. 2011;24(6):846–54. doi:10.1038/modpathol.2011.12.PubMedView ArticleGoogle Scholar
- Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol. 2005;23(31):7911–8. doi:10.1200/JCO.2005.02.9363.PubMedView ArticleGoogle Scholar
- Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11(10):3686–96. doi:10.1158/1078-0432.CCR-04-2398.PubMedView ArticleGoogle Scholar
- O'Neill CJ, Deavers MT, Malpica A, Foster H, McCluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol. 2005;29(8):1034–41.PubMedGoogle Scholar
- Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29(2):218–24.PubMedView ArticleGoogle Scholar
- Singer G, Oldt 3rd R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95(6):484–6.PubMedView ArticleGoogle Scholar
- Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012;226(3):413–20. doi:10.1002/path.3967.PubMed CentralPubMedView ArticleGoogle Scholar
- Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460(3):237–49. doi:10.1007/s00428-012-1203-5.PubMedView ArticleGoogle Scholar
- Gershenson DM. The life and times of low-grade serous carcinoma of the ovary. Am Soc Clin Oncol Educ Book. 2013. doi:10.1200/EdBook_AM.2013.33.e195.Google Scholar
- Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol. 2009;114(1):48–52. doi:10.1016/j.ygyno.2009.03.001.PubMedView ArticleGoogle Scholar
- Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14(2):134–40. doi:10.1016/s1470-2045(12)70572-7.PubMed CentralPubMedView ArticleGoogle Scholar
- Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229(1):111–20. doi:10.1002/path.4088.PubMedView ArticleGoogle Scholar
- Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682–9.PubMedGoogle Scholar
- Cuatrecasas M, Villanueva A, Matias-Guiu X, Prat J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer. 1997;79(8):1581–6.PubMedView ArticleGoogle Scholar
- Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003;90(2):378–81.PubMedView ArticleGoogle Scholar
- Nodin B, Zendehrokh N, Sundstrom M, Jirstrom K. Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagnostic Pathol. 2013;8:106. doi:10.1186/1746-1596-8-106.View ArticleGoogle Scholar
- Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Curr Oncol Rep. 2014;16(6):389. doi:10.1007/s11912-014-0389-x.PubMed CentralPubMedView ArticleGoogle Scholar
- Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, et al. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol. 2011;64(12):1097–101. doi:10.1136/jclinpath-2011-200082.PubMedView ArticleGoogle Scholar
- Chay WY, Chew SH, Ong WS, Busmanis I, Li X, Thung S, et al. HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS One. 2013;8(4), e61565. doi:10.1371/journal.pone.0061565.PubMed CentralPubMedView ArticleGoogle Scholar
- Huang RY, Chen GB, Matsumura N, Lai HC, Mori S, Li J, et al. Histotype-specific copy-number alterations in ovarian cancer. BMC Med Genom. 2012;5:47. doi:10.1186/1755-8794-5-47.View ArticleGoogle Scholar
- McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433. doi:10.1186/1471-2407-9-433.PubMed CentralPubMedView ArticleGoogle Scholar
- Jain A, Ryan PD, Seiden MV. Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location. J Natl Compr Canc Netw. 2012;10(9):1076–80.PubMedGoogle Scholar
- Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422–30. doi:10.1158/1078-0432.ccr-05-0508.PubMedView ArticleGoogle Scholar
- Schwartz DR, Kardia SL, Shedden KA, Kuick R, Michailidis G, Taylor JM, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62(16):4722–9.PubMedGoogle Scholar
- Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011;6(7), e21121. doi:10.1371/journal.pone.0021121.PubMed CentralPubMedView ArticleGoogle Scholar
- Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas. N Engl J Med. 2010;363(16):1532–43. doi:doi:10.1056/NEJMoa1008433.PubMed CentralPubMedView ArticleGoogle Scholar
- Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22(8):1310–5. doi:10.1097/IGC.0b013e31826b5dcc.PubMed CentralPubMedView ArticleGoogle Scholar
- Guan B, Wang TL, Shih IM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718–27. doi:10.1158/0008-5472.can-11-1562.PubMed CentralPubMedView ArticleGoogle Scholar
- Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL et al. Roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Nat Cancer Inst. 2014;106(7). doi:10.1093/jnci/dju146.Google Scholar
- Huang HN, Lin MC, Huang WC, Chiang YC, Kuo KT. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod Pathol. 2014;27(7):983–90. doi:10.1038/modpathol.2013.216.PubMedView ArticleGoogle Scholar
- Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597–601. doi:10.2353/ajpath.2009.081000.PubMed CentralPubMedView ArticleGoogle Scholar
- Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, et al. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma. Oncol Rep. 2014;32(2):553–8. doi:10.3892/or.2014.3268.PubMedGoogle Scholar
- Samartzis EP, Gutsche K, Dedes KJ, Fink D, Stucki M, Imesch P. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget. 2014;5(14):5295–303.PubMed CentralPubMedView ArticleGoogle Scholar
- Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, Banon-Rodriguez I, Hernandez-Cortes G, Hardisson D, et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol. 2006;37(8):1042–9. doi:10.1016/j.humpath.2006.03.003.PubMedView ArticleGoogle Scholar
- Geyer JT, Lopez-Garcia MA, Sanchez-Estevez C, Sarrio D, Moreno-Bueno G, Franceschetti I, et al. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol. 2009;33(8):1157–63. doi:10.1097/PAS.0b013e3181a902e1.PubMedView ArticleGoogle Scholar
- Gadducci A, Lanfredini N, Tana R. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gynecol Endocrinol. 2014;30(9):612–7. doi:10.3109/09513590.2014.926325.PubMedView ArticleGoogle Scholar
- Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35(5):625–32. doi:10.1097/PAS.0b013e318212782a.PubMed CentralPubMedView ArticleGoogle Scholar
- Wu RC, Wang TL, Shih IM. The emerging roles of ARID1A in tumor suppression. Canc Biol Ther. 2014;15(6):655–64. doi:10.4161/cbt.28411.View ArticleGoogle Scholar
- Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, et al. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer. 2014;14:120. doi:10.1186/1471-2407-14-120.PubMed CentralPubMedView ArticleGoogle Scholar
- Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60(24):7052–6.PubMedGoogle Scholar
- Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64(21):7678–81. doi:10.1158/0008-5472.can-04-2933.PubMedView ArticleGoogle Scholar
- Werner HM, Berg A, Wik E, Birkeland E, Krakstad C, Kusonmano K, et al. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Mod Pathol. 2013;26(3):428–34. doi:10.1038/modpathol.2012.174.PubMedView ArticleGoogle Scholar
- Oliva E, Sarrio D, Brachtel EF, Sanchez-Estevez C, Soslow RA, Moreno-Bueno G, et al. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. J Pathol. 2006;208(5):708–13. doi:10.1002/path.1923.PubMedView ArticleGoogle Scholar
- Aysal A, Karnezis A, Medhi I, Grenert JP, Zaloudek CJ, Rabban JT. Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability. Am J Surg Pathol. 2012;36(2):163–72. doi:10.1097/PAS.0b013e31823bc434.PubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.